$0.26
+0.01 (+4.08%)
Open$0.25
Previous Close$0.25
Day High$0.26
Day Low$0.25
52W High$0.86
52W Low$0.16
Volume—
Avg Volume30.96M
Market Cap11.08M
P/E Ratio—
EPS$-2.50
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+14,796.2% upside
Current
$0.26
$0.26
Target
$38.73
$38.73
$26.34
$38.73 avg
$46.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.08M | 955.9K |
| Net Income | -22,361 | -31,787 | -25,174 |
| Profit Margin | -2.2% | -2.9% | -2.6% |
| EBITDA | -38,355 | -35,389 | -33,870 |
| Free Cash Flow | -18,843 | -19,077 | -22,857 |
| Rev Growth | +0.6% | -3.8% | +4.7% |
| Debt/Equity | 0.84 | 0.93 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |